Angiogenic factors expressed by human prostatic cell lines: Effect on endothelial cell growth in vitro

Prostate

Volumn 33, Issue 2, 1997, Pages 123-132

  Hepburn, Peter J ^a   Griffiths, Keith ^a   Harper, Maureen E ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Tenovus Inst Cancer Res   (United Kingdom)

Author keywords

Coculture; Endothelial cells; FGF 2; Proliferation; Prostatic carcinoma cells

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CULTURE MEDIUM; GROWTH REGULATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VASCULARIZATION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ADRENAL CORTEX; ANGIOGENESIS INDUCING AGENTS; ANIMALS; AORTA, THORACIC; CAPILLARIES; CATTLE; CELL LINE; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; UMBILICAL VEINS;

EID: 0030770377     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19971001)33:2<123::AID-PROS6>3.0.CO;2-L     Document Type: Article

References (59)

1. Brawer MK: The diagnosis of prostatic cancer. Cancer [Suppl] 1993;71:899-905.
2. Lu-Yao GL, Greenberg ER: Changes in prostate cancer incidence and treatment in USA. Lancet 1994;343:251-254.
3. Majeed FA, Burgess NA: Trends in death rates and registration rates for prostate cancer in England and Wales. Br J Urol 1994; 73:377-381.
4. Folkman J, Klagsbrun M: Angiogenic factors. Science 1987;235: 442-447.
5. Baillie CT, Winslet MC, Bradley NJ: Tumour vasculature - A potential therapeutic target. Br J Cancer 1995;72:257-267.
6. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-761.
7. Yamazaki K, Abe S, Takekawa H, Sukoh N, Watanabe N, Ogura S, Nakajima I, Isobe H, Inoue K, Kawakami Y: Tumor angiogenesis in human lung adenocarcinoma. Cancer 1994;74:2245-2250.
8. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis. A new significant and independent prognostic indicator in early stage breast carcinoma. JNCI 1992;84:1875-1887.
9. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
10. Vukanovic J, Hartley-Asp B, Isaacs JT: Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancer. Prostate 1995;26:235-246.
11. Zugmaeir G, Lippman ME, Wellstein A: Inhibition by pentostan polypsulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. JNCI 1992;84:1716-1724.
12. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the growth of hormone independent human breast and prostate carcinoma cell lines. Cancer Res 1993;53:5233-5236.
13. Brindle NPJ: Growth factors in endothelial regeneration. Cardiovasc Res 1993;27:1162-1172.
14. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995;55:510-513.
15. Benharroch D, Birnbaum D: Biology of the fibroblast growth factor gene family. Isr J Med Sci 1990;26:212-219.
16. Basilico C, Moscatelli D: The FGF family of growth factor oncogenes. Adv Cancer Res 1992;59:115-165.
17. Ono M, Okamura K, Nakayama Y, Tomita M, Sato Y, Komatsu Y, Kuwano M: Induction of human microvascular endothelial tubular morphogenesis by human keratinocytes: Involvement of transforming growth factor-alpha. Biochem Biophys Res Commun 1992;189:601-609.
18. Harper ME, Goddard L, Glynne-Jones E, Wilson DW, Price Thomas M, Peeling WB, Griffiths K: An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumors. Prostate 1993;23:9-24.
19. Harper ME, Sibley PEC, Rowlands A, Buttifant L, Beacock C, Griffiths K: Hormonal modulation of the growth of a new transplantable prostatic cell line in athymic nude mice. Urol Res 1986;14:156.
20. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-281.
21. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
22. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Freidman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA: The LNCaP cell line - A new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-132.
23. Gingrich JR, Tucker JA, Walther PJ, Day JW, Poulton SH, Webb KS: Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). J Urol 1991;146:915-919.
24. Edgell C-JS, McDonald CC, Graham JB: Permanent cell line expressing human factor VIII related antigen established by hybridization. Proc Natl Acad Sci USA 1983;80:3734-3737.
25. Takahashi JA, Fukumoto M, Kozai Y, Ito N, Oda Y, Kikuchi H, Hatanaka M: Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett 1991;288:65-71.
26. Nakamato T, Chang CS, Li AK, Chodak GW: Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992; 52:571-577.
27. Hannan RL, Kourembanas S, Flanders KC, Rogelj SJ, Roberts AB, Faller DV, Klagsburn M: Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta. Growth Factors 1988;1:7-17.
28. Augustin-Voss HC, Voss AK, Pauli BU: Senescence of aortic endothelial cells in culture: Effects of basic fibroblast growth factor expression on cell phenotype, migration, and proliferation. J Cell Physiol 1993;157:279-288.
29. Connolly JM, Rose DP: Secretion of epidermal growth factor and related polypeptides by the DU145 cell line. Prostate 1989; 15:1-12.
30. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K: Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996;74:910-916.
31. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E: Differential effects of transforming growth factor beta on human prostate cells in vitro. Mol Cell Endocrinol 1989;62:79-87.
32. Glynne-Jones E, Harper ME, Goddard L, Eaton CL, Matthews PN, Griffiths K: Transforming growth factor beta 1 expression in benign and malignant prostatic tumors. Prostate 1994;25:210-218.
33. Ito K, Abe T, Tomita M, Morimoto A, Kohno K, Mori T, Ono M, Sugenoya A, Nishihira T, Kuwano M: Anti-angiogenic activity of arachidonic acid metabolism inhibitors in angiogenesis model systems involving human microvascular endothelial cells and neovascularization in mice. Int J Cancer 1993;55:660-666.
34. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL: Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 1995;44: 98-103.
35. Merwin JR, Newman W, Beall LD, Tucker A, Madri J: Vascular cells behave differentially to transforming growth factor beta 1 and beta 2 in vitro. Am J Pathol 1991;138:37-51.
36. Glynne-Jones E, Goddard L, Harper ME: Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 1996;27:688-694.
37. Raychaudhury A, D'Amore PA: Endothelial cell regulation by transforming growth factor-beta. J Cell Biochem 1991;47:224-229.
38. Gajdusek CM, Luo Z, Mayberg MR: Basic fibroblast growth factor and transforming growth factor beta-1: Synergistic mediators of angiogenesis in vitro. J Cell Physiol 1993;157:133-144.
39. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ: Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994;5:89-97.
40. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844.
41. Cleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51: 3753-3761.
42. Vesalainen S, Lipponen P, Talja M, Alhava E, Syrjanen K: Tumor vascularity and basement membrane structure as prognostic factors in T1,2 MO prostatic adenocarcinoma. Anticancer Res 1994;14:709-714.
43. Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, von Eschenbach AC: Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 1994;44:869-875.
44. Bouck N: Tumor angiogenesis. The role of oncogenes and tumor suppressor genes. Cancer Cells 1990;2:179-185.
45. Schulze-Osthoff K, Risau W, Vollmer E, Sorg C: In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol 1990;137:85-92.
46. Pepper MS, Ferrara N, Orci L, Montesano R: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenisis in vitro. Biochem Biophys Res Commun 1992;189:824-831.
47. Norioka K, Mitaka T, Mochizuki Y, Hara M, Kawagoe M, Nakamura H: Interaction of interleukin-1 and interferon-gamma on fibroblast growth factor-induced angiogenesis. Jpn J Cancer Res 1994;85:522-529.
48. 2 activity. J Biol Chem 1994;269:3219-3225.
49. Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashma T, Yamashita J, Yamamoto H: Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995;270:28316-28324.
50. Soker S, Fidder H, Neufeld G, Klagsbrun M: Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 1996;271:5761-5767.
51. Guo D, Jia Q, Song HY, Warren RS, Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 1995; 270:6729-6733.
52. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995.
53. Madri JA, Bell L, Merwin JR: Modulation of vascular cell behavior by transforming growth factors β. Mol Reprod Dev 1992; 32:121-126.
54. Morello JP, Plamondon J, Meyrick B, Hoover R, McCourt O'C: Transforming growth factor-beta receptor expression on endothelial cells: Heterogeneity of type III receptor expression. J Cell Physiol 1995;165:201-211.
55. Wang JM, Kumar S, van Agthoven A, Kumar P, Pye D, Hunter RD: Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells. Int J Cancer 1995;62:791-796.
56. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992;267:19027-19030.
57. Hirai R, Kaji K: Transforming growth factor beta 1-specific binding proteins on human vascular endothelial cells. Exp Cell Res 1992;201:119-125.
58. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
59. Toi M: Endothelial growth factors: A target for antiangiogenesis. Cancer J 1995;8:315-319.